Stay updated with breaking news from Lilly Media. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through...
Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose loggingData shared through platform interface may help healthcare...
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration News provided by Share this article MiNA Therapeutics Logo INDIANAPOLIS and LONDON, May 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform. Under the terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across ...
Press release content from PR Newswire. The AP news staff was not involved in its creation. Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes May 6, 2021 GMT Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS, May 6, 2021 /PRNewswire/ -- With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic international agreements with four companies – DexCom, Inc., G...